Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week Low – What’s Next?

Royalty Pharma plc (NASDAQ:RPRX) hit a new 52-week low during trading on Wednesday . The stock traded as low as $25.10 and last traded at $25.12, with a volume of 757826 shares traded. The stock had previously closed at $25.59.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on RPRX shares. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. Citigroup decreased their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, October 25th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Royalty Pharma presently has an average rating of “Moderate Buy” and an average price target of $41.67.

Royalty Pharma Stock Performance

The business has a 50-day moving average price of $26.77 and a 200 day moving average price of $27.23. The stock has a market capitalization of $14.64 billion, a P/E ratio of 13.06, a PEG ratio of 4.43 and a beta of 0.46. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Friday, November 15th were given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 3.38%. The ex-dividend date of this dividend was Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Hedge Funds Weigh In On Royalty Pharma

A number of hedge funds have recently added to or reduced their stakes in RPRX. Blue Trust Inc. boosted its holdings in shares of Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 943 shares during the last quarter. Gladius Capital Management LP purchased a new stake in Royalty Pharma in the second quarter worth approximately $32,000. Wilmington Savings Fund Society FSB bought a new stake in Royalty Pharma in the 3rd quarter worth approximately $61,000. EverSource Wealth Advisors LLC raised its stake in Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 655 shares during the last quarter. Finally, Transamerica Financial Advisors Inc. lifted its holdings in shares of Royalty Pharma by 99.9% during the 3rd quarter. Transamerica Financial Advisors Inc. now owns 3,459 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,729 shares during the period. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.